» Articles » PMID: 27110495

Synthesis and Antiproliferative Activities of Benzimidazole-Based Sulfide and Sulfoxide Derivatives

Overview
Journal Sci Pharm
Publisher MDPI
Specialty Pharmacology
Date 2016 Apr 26
PMID 27110495
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The design, synthesis, and in vitro antiproliferative activity of a novel series of sulfide (4a-i) and sulfoxide (5a-h) derivatives of benzimidazole, in which different aromatic and heteroaromatic acetamides are linked to benzimidazole via sulfide (4a-i) and sulfoxide (5a-h) linker, are reported and the structure-activity relationship is discussed. The new derivatives were prepared by coupling 2-(mercaptomethyl)benzimidazole with 2-bromo-N-(substituted) acetamides in dry acetone in the presence of anhydrous potassium carbonate. With very few exceptions, all of the synthesized compounds showed varying antiprolific activities against HepG2, MCF-7, and A549 cell lines. Compound 5a was very similar in potency to doxorubicin as an anticancer drug, with IC50 values 4.1 ± 0.5, 4.1 ± 0.5, and 5.0 ± 0.6 µg/mL versus 4.2 ± 0.5, 4.9 ± 0.6, and 6.1 ± 0.6 µg/mL against HepG2, MCF-7, and A549 cell lines, respectively. In contrast, none of the compounds showed activity against human prostate PC3 cancer cells. Additionally, the sulfoxide derivatives were more potent than the corresponding sulfides.

Citing Articles

Synthesis and Antifungal Potential of Some Novel Benzimidazole-1,3,4-Oxadiazole Compounds.

Karaburun A, Kaya Cavusoglu B, Acar Cevik U, Osmaniye D, Saglik B, Levent S Molecules. 2019; 24(1).

PMID: 30621357 PMC: 6337182. DOI: 10.3390/molecules24010191.

References
1.
Kirubakaran S, Gorla S, Sharling L, Zhang M, Liu X, Ray S . Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH. Bioorg Med Chem Lett. 2012; 22(5):1985-8. PMC: 3289519. DOI: 10.1016/j.bmcl.2012.01.029. View

2.
Cheson B, Wendtner C, Pieper A, Dreyling M, Friedberg J, Hoelzer D . Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk. 2010; 10(1):21-7. DOI: 10.3816/CLML.2010.n.002. View

3.
Porcari A, Devivar R, Kucera L, DRACH J, Townsend L . Design, synthesis, and antiviral evaluations of 1-(substituted benzyl)-2-substituted-5,6-dichlorobenzimidazoles as nonnucleoside analogues of 2,5,6-trichloro-1-(beta-D-ribofuranosyl)benzimidazole. J Med Chem. 1998; 41(8):1252-62. DOI: 10.1021/jm970559i. View

4.
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D . New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82(13):1107-12. DOI: 10.1093/jnci/82.13.1107. View

5.
Harrison M, Holen K, Liu G . Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol. 2009; 7(1):54-64. PMC: 2904974. View